Cortisone

Cortisone is a short-acting glucocorticoid used in veterinary medicine to manage inflammatory conditions, allergic reactions, and certain immune-mediated disorders in dogs. As a prodrug, cortisone itself is biologically inactive and must be converted to hydrocortisone in the liver before exerting its therapeutic effects. This conversion process makes cortisone functionally equivalent to hydrocortisone once metabolized, providing the same anti-inflammatory and immunosuppressive benefits. Cortisone has a long history of medical use and remains an option in canine therapeutics, though hydrocortisone and other more commonly prescribed corticosteroids often take precedence in contemporary veterinary practice.

The mechanism of action of cortisone, once converted to its active form hydrocortisone, involves binding to glucocorticoid receptors found throughout the body. The drug-receptor complex then modulates gene expression in the cell nucleus, resulting in decreased production of inflammatory mediators including prostaglandins, leukotrienes, and various cytokines. This leads to reduced inflammation, swelling, redness, and pain in affected tissues. The immunosuppressive effects result from inhibition of lymphocyte function and decreased antibody production. Cortisone's classification as a short-acting corticosteroid means its effects typically last eight to twelve hours, allowing flexibility in dosing and relatively quick resolution of drug effects after discontinuation.

Cortisone is available primarily in oral tablet form and as cortisone acetate injectable suspension for intramuscular or intra-articular administration. Oral tablets are used for systemic inflammatory conditions requiring consistent drug levels, while injectable forms may be used for localized joint inflammation or when oral administration is not feasible. The requirement for hepatic conversion means that dogs with significant liver disease may not effectively activate cortisone, making hydrocortisone or other already-active corticosteroids preferable in these patients. Dosing frequency typically involves multiple daily administrations due to the short duration of action.

The safety profile of cortisone in dogs is similar to other corticosteroids, with the potential for various adverse effects particularly during prolonged use. The short duration of action may offer some advantages in terms of allowing recovery of natural cortisol rhythms between doses. However, all corticosteroids carry risks of increased thirst and urination, increased appetite, gastrointestinal effects, and with long-term use, more serious metabolic and immunological consequences. Veterinary supervision is essential for determining appropriate use, dosing, duration of treatment, and monitoring during cortisone therapy.

The primary indications for cortisone in dogs encompass a range of inflammatory and immune-mediated conditions where corticosteroid therapy provides therapeutic benefit. As a short-acting glucocorticoid, cortisone is suitable for conditions requiring flexible dosing and situations where a less potent or shorter-duration corticosteroid is preferred. While cortisone has been largely supplanted by more commonly used corticosteroids such as prednisone and prednisolone in many veterinary practices, it remains a valid therapeutic option when other corticosteroids are unavailable or when specific clinical circumstances favor its use.

Acute inflammatory conditions represent common indications for cortisone use in dogs. Trauma-induced inflammation, post-surgical swelling, and musculoskeletal injuries may respond to short courses of cortisone therapy. The medication helps reduce pain, swelling, and inflammation associated with these conditions, improving patient comfort and potentially speeding recovery. Inflammatory joint conditions, including some forms of arthritis, may be treated with cortisone, either systemically through oral administration or locally through intra-articular injection of cortisone acetate suspension for targeted relief of specific joints.

Allergic conditions in dogs frequently warrant corticosteroid intervention, and cortisone can provide relief from the inflammation and immune activation characteristic of allergic responses. Acute allergic reactions, including those caused by insect stings, contact allergens, or dietary triggers, may be treated with cortisone to reduce symptoms. Chronic allergic dermatitis may be managed with cortisone therapy, though newer medications with fewer systemic effects have become preferred for long-term management of allergic skin conditions. The short duration of action allows for responsive dose adjustments based on symptom control.

Autoimmune and immune-mediated disorders sometimes require corticosteroid therapy to suppress excessive immune system activity. Conditions such as immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, and certain types of inflammatory bowel disease may be treated with cortisone, though more potent corticosteroids are often chosen for these serious conditions requiring significant immunosuppression. Cortisone may serve as part of a tapering protocol when transitioning from higher-potency corticosteroids to minimize long-term steroid exposure.

The selection of cortisone over alternative corticosteroids depends on multiple factors including availability, cost, required potency, and patient-specific considerations. Cortisone's lower potency compared to synthetic corticosteroids like prednisone or dexamethasone may be preferred when a milder anti-inflammatory effect is desired. The need for hepatic conversion to the active form makes cortisone less suitable for dogs with liver disease. Veterinarians consider these factors alongside patient history and concurrent medications when selecting the most appropriate corticosteroid for each individual case.

Dosing of cortisone in dogs is determined by the veterinarian based on careful evaluation of the patient's condition, body weight, and expected response to therapy. Because cortisone is a prodrug requiring hepatic conversion to active hydrocortisone, dosing must account for this conversion process and its potential variability among individual patients. Accurate weight measurement is essential for calculating appropriate doses, particularly important given the wide size range of dogs from toy breeds to giant breeds. Pet owners should administer cortisone exactly as prescribed and never adjust doses without veterinary guidance.

Typical dosing protocols for cortisone vary based on the indication being treated. Anti-inflammatory doses are generally calculated on a milligram per kilogram basis, with the specific dose depending on the severity of inflammation and desired therapeutic effect. Because cortisone has approximately 80% of the glucocorticoid potency of hydrocortisone after conversion, doses may be somewhat higher than would be used for hydrocortisone to achieve equivalent effects. The short duration of action typically necessitates divided daily dosing, with administration two to four times daily being common to maintain consistent therapeutic effect throughout the day.

Treatment duration with cortisone depends on the condition being treated and patient response. Acute inflammatory conditions may require only days to one or two weeks of therapy, while chronic conditions might necessitate longer treatment periods. Regardless of treatment length, cortisone should not be discontinued abruptly after more than a few days of use. Gradual dose tapering allows the adrenal glands to resume normal cortisol production, which is suppressed during corticosteroid therapy. Your veterinarian will provide specific tapering instructions based on the duration and dose of treatment.

Oral cortisone tablets should be administered with food to reduce the risk of gastrointestinal irritation, a common side effect of corticosteroid therapy. The medication can be given directly by mouth or hidden in a small treat or pill pocket for dogs that are reluctant to take pills. Consistency in administration timing helps maintain stable drug levels. For injectable cortisone acetate, administration is typically performed by veterinary professionals, with intramuscular injection providing systemic effects and intra-articular injection targeting specific joints for localized conditions.

If a dose of cortisone is missed, it should be given as soon as the owner remembers, unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular schedule resumed. Doubling doses to make up for missed ones should never be done, as this increases the risk of adverse effects. If multiple doses are missed or if there are concerns about maintaining the dosing schedule, owners should contact their veterinarian for guidance.

Completion of the prescribed treatment course is important for achieving therapeutic goals and preventing complications. For inflammatory conditions, adequate treatment duration helps ensure complete resolution rather than temporary improvement followed by relapse. For tapering protocols, following the prescribed schedule prevents withdrawal effects and adrenal crisis. Owners should communicate with their veterinarian if they have concerns about continuing treatment or if side effects are affecting their dog's quality of life.

Cortisone, like all corticosteroids, can produce a range of side effects related to its anti-inflammatory, immunosuppressive, and metabolic actions. Because cortisone must be converted to hydrocortisone in the liver before becoming active, its side effect profile is essentially identical to that of hydrocortisone. Most dogs tolerate cortisone well when used at appropriate doses for limited durations, but owners should be aware of potential adverse effects to facilitate early detection and intervention when needed. The short-acting nature of cortisone means that side effects generally resolve more quickly upon discontinuation compared to longer-acting corticosteroids.

The most commonly observed side effects of cortisone in dogs are related to the medication's effects on metabolism and fluid balance. Increased thirst and correspondingly increased urination are hallmark effects of corticosteroid therapy, sometimes requiring owners to provide more frequent opportunities for their dog to go outside. Increased appetite is another frequent observation that can lead to weight gain if food intake is not monitored. Dogs may appear more restless, pant more than usual, or seem generally more active than normal. These effects are dose-dependent and typically resolve when the medication is discontinued.

Gastrointestinal side effects are common with oral cortisone therapy. Increased stomach acid production can lead to nausea, vomiting, decreased appetite paradoxically in some dogs, or diarrhea. More serious gastrointestinal complications include gastric ulceration and bleeding, which may present as dark tarry stools, vomiting blood, weakness, or signs of abdominal pain. Administering cortisone with food helps reduce gastrointestinal irritation. Dogs receiving concurrent non-steroidal anti-inflammatory drugs are at much higher risk for gastrointestinal complications, and this combination should be avoided.

Longer-term cortisone use can lead to more significant adverse effects reflecting chronic corticosteroid exposure. Iatrogenic Cushing's syndrome, resulting from prolonged elevated cortisol levels, may develop with extended treatment. Signs include a pot-bellied appearance, hair loss, thin skin, increased susceptibility to infections, and muscle weakness. Suppression of the adrenal glands' natural cortisol production is another consequence of prolonged therapy, making gradual tapering essential when discontinuing treatment. Effects on the immune system increase vulnerability to bacterial, viral, and fungal infections.

Serious side effects requiring immediate veterinary attention include signs of gastrointestinal bleeding, severe weakness or collapse, difficulty breathing, or any indication of significant infection. Because corticosteroids can mask signs of infection, owners should be vigilant for subtle changes suggesting their dog may be unwell. Dogs with diabetes may experience worsening blood glucose control during cortisone therapy. Any concerning symptoms should prompt consultation with the prescribing veterinarian to determine whether dose adjustment or treatment modification is needed.

Cortisone should not be used in dogs with known hypersensitivity to cortisone or other corticosteroids. While true allergic reactions to corticosteroids are uncommon, dogs that have experienced previous adverse reactions should not receive these medications without careful veterinary evaluation. More commonly, contraindications for cortisone relate to conditions that may be worsened by corticosteroid effects, including immunosuppression, metabolic changes, and gastrointestinal effects.

Active systemic infections represent important contraindications for cortisone use. Fungal infections including blastomycosis, histoplasmosis, coccidioidomycosis, and other mycotic diseases can spread rapidly when the immune system is suppressed by corticosteroids. Dogs with these conditions should not receive cortisone until the infection is adequately controlled. Active viral infections may also be worsened by corticosteroid-induced immunosuppression. Bacterial infections require careful consideration, as cortisone can mask infection signs while allowing bacterial proliferation, though concurrent antibiotic therapy may permit cautious use in some situations.

Significant liver disease is a unique contraindication for cortisone compared to other corticosteroids. Because cortisone is a prodrug requiring hepatic conversion to active hydrocortisone, dogs with liver dysfunction may not effectively activate the medication. This results in unpredictable therapeutic effects and makes already-active corticosteroids like hydrocortisone or prednisolone more appropriate choices for dogs with hepatic impairment. Kidney disease also warrants caution, as corticosteroids can affect fluid balance and electrolyte handling.

Gastrointestinal ulceration or a history of gastric ulcers requires careful evaluation before cortisone administration. Corticosteroids promote gastric acid secretion and can impair protective mechanisms in the stomach lining, increasing the risk of ulcer development or worsening. Dogs with diabetes mellitus may experience significant hyperglycemia when receiving corticosteroids, necessitating close monitoring and potential insulin dose adjustments. Pregnancy and nursing represent relative contraindications, as corticosteroids can affect fetal development and are passed through milk to nursing puppies. Young puppies with developing immune systems and older dogs with compromised organ function also require careful consideration before starting cortisone therapy.

Complete disclosure of all medications and supplements a dog is receiving is essential before initiating cortisone therapy. Drug interactions with cortisone can occur through various mechanisms, including additive effects on target organs, altered drug metabolism, and interference with drug action. Because cortisone requires hepatic conversion to its active form, medications affecting liver enzyme activity may have particular relevance. Veterinarians rely on accurate medication histories to anticipate and prevent potentially harmful interactions.

The most significant drug interaction involving cortisone, as with all corticosteroids, is with non-steroidal anti-inflammatory drugs. Concurrent use of cortisone and NSAIDs dramatically increases the risk of gastrointestinal ulceration and bleeding, a potentially life-threatening complication. This combination should be avoided whenever possible. If both drug classes are considered necessary, they should be used at the lowest effective doses for the shortest possible time, with gastroprotective therapy. A washout period is recommended when transitioning between NSAIDs and corticosteroids.

Medications affecting hepatic cytochrome P450 enzymes can alter cortisone metabolism and conversion to hydrocortisone. Drugs that induce liver enzymes, such as phenobarbital, may increase the rate of cortisone metabolism, potentially reducing therapeutic effect. Conversely, drugs that inhibit hepatic enzymes may slow cortisone conversion and metabolism. These interactions can result in either inadequate therapy or increased risk of adverse effects, depending on the specific medication combination.

Cortisone can interact with medications affecting glucose metabolism and electrolyte balance. Diabetic dogs receiving insulin or oral hypoglycemic agents may require dose adjustments when cortisone is added or discontinued, as corticosteroids promote hyperglycemia. Diuretics, particularly those that promote potassium excretion, may have enhanced effects when combined with cortisone, which also causes some potassium loss. Cardiac glycosides like digoxin may have increased toxicity in the setting of cortisone-induced electrolyte disturbances.

Vaccines, particularly live vaccines, should not be administered to dogs receiving immunosuppressive doses of corticosteroids. The suppressed immune system may not mount an appropriate immune response and could potentially allow the vaccine organism to cause infection. Killed vaccines may be less effective during corticosteroid therapy. Supplements with anti-inflammatory or immune-modulating properties should be disclosed to the veterinarian. Regular monitoring allows for detection of interaction effects and appropriate treatment modifications.

General precautions for cortisone use in dogs emphasize careful patient selection, appropriate dosing, and regular monitoring throughout treatment. As a corticosteroid with multiple physiological effects, cortisone requires thoughtful use under veterinary supervision. Accurate weight determination is essential for proper dosing, and owners should follow prescription instructions precisely. Because cortisone requires hepatic conversion to become active, dogs with liver disease may be poor candidates for this particular corticosteroid. Regular veterinary follow-up allows for assessment of therapeutic response and early detection of adverse effects.

Breed-specific concerns with cortisone relate primarily to underlying health predispositions rather than variations in drug metabolism. Unlike some medications affected by the MDR1 gene mutation common in herding breeds, cortisone is not known to have altered effects in these dogs. However, breeds predisposed to certain conditions may require additional monitoring during corticosteroid therapy. Breeds prone to diabetes mellitus should have blood glucose monitored carefully. Breeds predisposed to Cushing's disease should be observed for signs of iatrogenic hyperadrenocorticism. Breeds with gastrointestinal sensitivities may be at higher risk for corticosteroid-related stomach upset.

Environmental and handling precautions focus on safe medication storage and preventing accidental exposure. Cortisone should be stored in its original container in a secure location away from pets and children. Dropped tablets should be recovered immediately to prevent accidental ingestion by other animals in the household. When handling the medication, good hygiene practices should be followed. Unused or expired medication should be disposed of properly through pharmacy take-back programs or veterinary clinics rather than flushed or placed in regular trash.

Monitoring during cortisone treatment includes observation for both therapeutic response and potential adverse effects. Owners should note changes in their dog's inflammatory symptoms, activity level, appetite, thirst, urination, and overall demeanor. Signs suggesting gastrointestinal problems, unusual weakness, or infection should be reported to the veterinarian promptly. Longer-term therapy may warrant periodic blood work to assess liver function, blood glucose, and electrolyte balance. Dogs should be monitored for signs of Cushing's syndrome if treatment is prolonged.

Special populations requiring additional consideration include geriatric dogs, who may have reduced hepatic function affecting cortisone conversion and overall drug handling. Senior dogs are also more likely to have concurrent conditions that may be affected by corticosteroid therapy. Puppies have developing organ systems and may respond differently to corticosteroids than adult dogs. Dogs with chronic diseases, including diabetes, heart disease, kidney disease, or immune disorders, require careful benefit-risk assessment before starting cortisone therapy. Pregnant and nursing dogs should receive cortisone only when clearly necessary.

Proper storage of cortisone ensures medication stability and prevents accidental exposure to household members or other pets. Oral tablets should be stored at controlled room temperature, typically between 68 and 77 degrees Fahrenheit, in a dry location protected from moisture and light. The original prescription container provides appropriate protection and clear labeling, and should be used unless alternative child-resistant packaging is provided. Storage locations with fluctuating temperature or humidity, such as bathrooms, kitchens, or vehicles, should be avoided.

Injectable cortisone acetate suspension has specific storage requirements that should be followed according to manufacturer instructions. This formulation typically requires room temperature storage and protection from freezing. The suspension should be shaken well before use to ensure uniform distribution of the drug particles. Multi-dose vials should be inspected before each use for signs of contamination, and proper aseptic technique should be used when withdrawing doses. Expired or contaminated injectable products should not be used.

Safety considerations for cortisone storage and handling protect all household members, including pets and children. While cortisone is not highly toxic in single accidental doses, significant ingestion could cause adverse effects. Medications should be stored in locations genuinely inaccessible to curious pets and children, remembering that dogs can be resourceful at obtaining items they find interesting. Child-resistant containers provide an additional safety layer but should not be the only precaution. If accidental ingestion occurs, poison control or veterinary guidance should be sought. Unused or expired cortisone should be disposed of through pharmacy take-back programs, veterinary clinics, or following DEA guidelines for household medication disposal.

Most dogs can safely receive cortisone regardless of breed, with dosing based on body weight and individual patient factors rather than breed-specific pharmacological variations. Cortisone is not among the medications known to have altered effects in breeds carrying the MDR1 gene mutation, so herding breeds such as Collies, Australian Shepherds, and Shetland Sheepdogs do not require special dosing considerations based on this genetic factor. However, breed predispositions to certain health conditions may influence the decision to use cortisone and guide monitoring during treatment.

Certain breeds have increased susceptibility to conditions that may complicate or require adjustment of corticosteroid therapy. Breeds predisposed to diabetes mellitus, including Samoyeds, Australian Terriers, and Miniature Schnauzers, may experience problematic hyperglycemia during cortisone treatment. Breeds prone to Cushing's disease, such as Poodles, Dachshunds, and Boston Terriers, should be monitored closely for signs of iatrogenic hyperadrenocorticism during prolonged therapy. Breeds with gastrointestinal sensitivities may have increased risk of corticosteroid-related gastric complications. These considerations inform treatment planning rather than precluding cortisone use entirely.

Size variations among dog breeds significantly impact cortisone dosing and administration. Toy breeds weighing less than 10 pounds require precise dosing that may be challenging with standard tablet formulations. Liquid formulations or accurately scored tablets help ensure appropriate doses for very small dogs. Giant breeds require larger absolute doses, which may involve multiple tablets per administration. Despite size differences, per-kilogram dosing remains consistent across breeds, making accurate weight measurement essential for all patients regardless of size.

Age-related considerations apply across all breeds when using cortisone. Puppies have developing hepatic systems that may convert cortisone to hydrocortisone differently than adult dogs, and their developing immune systems may be more sensitive to immunosuppressive effects. Corticosteroids can potentially affect growth in young animals, so use in puppies should be limited to situations where clearly necessary. Senior dogs, typically those over seven to ten years depending on size, often have reduced liver and kidney function that may affect drug metabolism and clearance. Geriatric patients may benefit from conservative starting doses and careful monitoring throughout treatment.

Within the short-acting corticosteroid category, hydrocortisone is the most closely related medication to cortisone, as cortisone is actually converted to hydrocortisone in the liver before becoming active. For dogs with normal liver function, the two medications are functionally equivalent once cortisone undergoes hepatic conversion. Hydrocortisone may be preferred for dogs with liver disease since it does not require activation. Both medications have similar durations of action, potency, and side effect profiles, making them largely interchangeable in dogs with normal hepatic function.

Intermediate-acting corticosteroids including prednisone, prednisolone, and methylprednisolone offer increased anti-inflammatory potency and longer duration of action compared to cortisone. These medications are approximately four times more potent than cortisone and have durations of action ranging from 12 to 36 hours. They are commonly chosen when more significant anti-inflammatory or immunosuppressive effects are needed. Long-acting corticosteroids such as dexamethasone and betamethasone provide the highest potency and longest duration, making them suitable for severe conditions or situations requiring sustained effect.

For conditions commonly treated with cortisone, alternative drug classes may be considered depending on the specific indication. Allergic skin conditions may be managed with newer immunomodulatory drugs such as oclacitinib or lokivetmab that provide relief from itching without systemic corticosteroid effects. Cyclosporine is another option for chronic allergic or immune-mediated conditions. Non-steroidal anti-inflammatory drugs address inflammation through different mechanisms but cannot be combined safely with corticosteroids and are not appropriate for immune-mediated conditions. Supportive therapies including omega-3 fatty acids, probiotics, and gastroprotective medications may complement cortisone therapy. Any medication changes should be made under veterinary guidance to ensure safety and efficacy.